You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 564 Potency-reduced and extended half-life IL12 heterodimeric Fc-fusions exhibit strong anti-tumor activity with potentially improved therapeutic index compared to native IL12 agents

Article metrics

Article menu

Download PDFPDF

Regular and young investigator award abstracts
Immune-stimulants and immune modulators
564 Potency-reduced and extended half-life IL12 heterodimeric Fc-fusions exhibit strong anti-tumor activity with potentially improved therapeutic index compared to native IL12 agents

 

Online download statistics by month:

Online download statistics by month: November 2020 to June 2025

AbstractFullPdf
Nov 2020131011
Dec 202053023
Jan 20212204
Feb 20213205
Mar 20212205
Apr 20212006
May 2021003
Jun 20210017
Jul 2021005
Aug 2021009
Sep 20210010
Oct 202140015
Nov 202146021
Dec 20212007
Jan 20224007
Feb 20221802
Mar 20223609
Apr 20224804
May 20225409
Jun 202252013
Jul 20223204
Aug 20223006
Sep 20222805
Oct 20223805
Nov 20222203
Dec 20223205
Jan 20235206
Feb 20232605
Mar 20233202
Apr 20234403
May 20233006
Jun 2023600
Jul 20231603
Aug 20231401
Sep 20231803
Oct 20231402
Nov 20232605
Dec 20233000
Jan 20241401
Feb 20243405
Mar 20241601
Apr 20243400
May 20243002
Jun 20242201
Jul 20243003
Aug 20241402
Sep 20244006
Oct 20244005
Nov 20244005
Dec 20243804
Jan 202526014
Feb 2025803
Mar 2025002
Apr 2025005
May 20250011
Jun 2025006
Total15100325